Bonnie An Henderson

Tufts University, Бостон, Georgia, United States

Are you Bonnie An Henderson?

Claim your profile

Publications (45)131.72 Total impact

  • No preview · Article · Nov 2015 · Journal of Cataract and Refractive Surgery
  • Source
    Bonnie An Henderson · Ivayla I. Geneva
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this review was to provide a summary of the peer-reviewed literature on the etiologies of negative dysphotopsia that occurs after routine cataract surgery. A search of PubMed, Google Scholar, and Retina Medical identified 59 reports. Negative dysphotopsia has been associated with many types of intraocular lenses (IOLs), including hydrophobic and hydrophilic acrylic, silicone, and 1-piece and 3-piece designs. Proposed etiologies include edge design, edge smoothness, edge thickness, index of refraction of the IOL, pupil size, amount of functional nasal retina, edema from the clear corneal incision, distance between the iris and IOL, amount of pigmentation of the eye, corneal shape, prominent globe and shallow orbit, and interaction between the anterior capsulorhexis and IOL. Treatments include a piggyback IOL, reverse optic capture, dilation of the pupil, constriction of the pupil, neodymium:YAG capsulotomy of the nasal portion of the anterior capsule, IOL exchange with round-edged optics, and time alone. This review summarizes the findings. Financial Disclosure Dr. Henderson is a consultant to Alcon Laboratories, Inc., Abbott Medical Optics, Inc., Bausch & Lomb, and Genzyme Corp. Neither author has a financial or proprietary interest in any material or method mentioned.
    Full-text · Article · Oct 2015 · Journal of Cataract and Refractive Surgery
  • Bonnie Henderson · Zuhair Sharif · Ivayla Geneva
    [Show abstract] [Hide abstract]
    ABSTRACT: Cataract surgeons have witnessed tremendous advances in instrumentation, materials, surgical technique, and technology over the past several decades that have enabled them to achieve excellent visual outcomes offering greater safety and greater range of vision after surgery. Critical to the great success of modern era cataract surgery has been the evolution in intraocular lens (IOL) technology and design. However, up until recently, IOL options were limited to monofocal lenses. These lenses are successful in providing uncorrected vision for one focal point but leave most individuals dependent on some correction for other distances. The newest wave of IOL innovation has provided surgeons with several alternatives with the goal of restoring the ability to focus both at near and far without complete dependence on spectacles. These lenses can be broadly divided into two categories:accommodating and non-accommodating, a.k.a.multifocal IOLs. Currently, there are four FDA approved IOLs available to treat presbyopia in the United States: Crystalens/Trulign (Bausch & Lomb, Rochester, NY), ReSTOR (Alcon, Fort Worth, TX), and Tecnis (Abbot Medical Optics, Irvine, CA). Similar to the boom of new technology that made new implants and devices available to cataract surgeons, the advances in communications have made information regarding cataract surgery readily available to patients to the point that nowadays patients come to the office well-prepared and up to date on their surgical options and have started to expect perfect surgical outcomes, with good vision at both distance and near without the need for corrective lenses.
    No preview · Chapter · Oct 2015
  • Bonnie An Henderson

    No preview · Article · Aug 2015 · Jama Ophthalmology
  • Source
    David F Chang · Rosa Braga-Mele · Bonnie An Henderson · Nick Mamalis · Abhay Vasavada
    [Show abstract] [Hide abstract]
    ABSTRACT: A 2014 online survey of the American Society of Cataract and Refractive Surgery members indicated increasing use of intracameral antibiotic injection prophylaxis compared with a comparable survey from 2007. Forty-seven percent of respondents already used or planned to adopt this measure. One half of all surgeons not using intracameral prophylaxis expressed concern about the risks of noncommercially prepared antibiotic preparations. Overall, the large majority (75%) said they believe it is important to have a commercially available antibiotic approved for intracameral injection. Assuming reasonable cost, the survey indicates that commercial availability of Aprokam (cefuroxime) would increase the overall percentage of surgeons using intracameral antibiotic injection prophylaxis to nearly 84%. Although the majority used topical perioperative antibiotic prophylaxis, and gatifloxacin and moxifloxacin were still the most popular agents, there was a trend toward declining use of fourth-generation fluoroquinolones (60%, down from 81% in 2007) and greater use of topical ofloxacin and ciprofloxacin (21%, up from 9% in 2007). Copyright © 2015 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
    Full-text · Article · Jun 2015 · Journal of Cataract and Refractive Surgery
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Endophthalmitis is a rare but potentially devastating complication of cataract surgery. This article presents an overview of endophthalmitis prophylaxis and the use of intracameral antibiotics. It highlights available intracameral antibiotics with respect to pharmacology, spectrum of activity, dosage and preparation, safety, and efficacy profiles, as well as toxic anterior segment syndrome risks to better define the potential use of these medications in the prevention of endophthalmitis. Proprietary or commercial disclosures are listed after the references. Copyright © 2014 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
    Full-text · Article · Nov 2014 · Journal of Cataract and Refractive Surgery
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective This study utilized a phone survey to characterize patient perceptions of cataract surgery and the manner in which the ophthalmologist contributes to the patient’s understanding in electing cataract surgery. Patients and methods Calls were made from a randomized membership list of the American Association of Retired Persons until 1,000 respondents 50 years of age or older had been recruited. Three groups were recruited: persons with no prior diagnosis of cataracts, persons diagnosed with cataracts but who had not had surgery, and persons who had had cataract surgery on both eyes within the past 5 years. A series of fixed-choice and open-ended questions was then presented to qualified participants. Questions related to vision, quality of life, and the understanding and perceptions of cataract surgery. Results Two-thirds of respondents reported having frequent eye examinations. More than half indicated that they had discussed cataract surgery with an eye doctor, most often with an ophthalmologist. They reported that the benefits of surgery were most often mentioned (68%), but lens options were infrequently mentioned (39%). Of those who had had surgery, 81% elected to do so on the advice of their health care professional. About 85% of respondents who had had surgery felt well educated about the procedure, though only 75% felt they understood their lens and vision options. Three-quarters of those who had had cataract surgery wished they had had the surgery sooner, and reported that they were enjoying life more after surgery. Conclusion The ophthalmologist plays an important role in preparing patients for cataract surgery. Discussing both the timing of the surgery and the patient’s lens options are critical for appropriate care; the survey results suggest room for improvement in this regard. Respondents reported they wished they had had surgery sooner, based primarily on their improved quality of life postoperatively.
    Full-text · Article · Aug 2014 · Clinical ophthalmology (Auckland, N.Z.)
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To compare the impact of varying fluidic parameters on intraoperative intraocular pressure (IOP) fluctuations and postoperative outcomes. Methods: Prospective randomized study of 80 eyes undergoing cataract surgery that were randomly assigned to low (aspiration flow rate: 20 cc/min; bottle height: 90 cm; vacuum: 400 mm Hg) and high (aspiration flow rate: 40 cc/min; bottle height: 110 cm; vacuum: 400 mm Hg) fluidic parameter groups. Real-time dynamic intraoperative IOP was measured during nuclear fragment removal. Mean maximum and minimum IOP and percentage reduction in IOP from maximum were compared between groups. Postoperatively, the rate of change in central corneal thickness and anterior chamber inflammation at days 1 and 7, endothelial cell density at 3 months, and corneal clarity on day 1 were compared. Results: Minimum IOP in the low and high parameters groups was 35 ± 4.0 and 34.5 ± 6.8 mm Hg, respectively. Maximum IOP in the low and high parameters groups was 69 ± 3.0 and 85 ± 1.2 mm Hg, respectively (P < .002). Mean percent reduction from maximum was 59% in the high parameters group compared to 41% in the low parameters group, with the difference being statistically significant (P < .002). Rate of change in central corneal thickness was greater in the high parameters group at postoperative days 1 and 7 (P < .001). Anterior chamber inflammation and corneal clarity on the first postoperative day were significantly better in the low parameters group. Conclusions: Higher aspiration flow rate and bottle heights are associated with high intraoperative IOPs of up to 85 mm Hg. Prolonged elevated IOP during cataract surgery was found to have more anterior segment inflammation and more edematous corneas.
    No preview · Article · Jul 2014 · Journal of refractive surgery (Thorofare, N.J.: 1995)
  • Source
    Ivayla Geneva · Bonnie Henderson

    Full-text · Conference Paper · Apr 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This article presents an extensive overview of best clinical practice pertaining to selection and use of multifocal intraocular lenses (IOLs) currently available in the United States. Relevant preoperative diagnostic evaluations, patient selection criteria, counseling, and managing expectations are reviewed, as well as how to approach patients with underlying ocular intricacies or challenges and best practices for intraoperative challenges during planned implantation of a multifocal IOL. Managing the unhappy multifocal IOL patient if implantation has been performed is also addressed. Financial Disclosure No author has a financial or proprietary interest in any material or method mentioned.
    Full-text · Article · Feb 2014 · Journal of Cataract and Refractive Surgery
  • Bonnie An Henderson

    No preview · Article · Jan 2014 · Journal of Cataract and Refractive Surgery
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the results of thin-flap laser in situ keratomileusis (LASIK) using a femtosecond-laser platform for flap creation. Institute of Vision and Optics, Faculty of Medicine, University of Crete, Heraklion, Greece. Prospective interventional case series. Patients had LASIK with the FS200 femtosecond laser for flap creation and the Allegretto Wave Eye-Q excimer laser. Flap thickness was set at 105 μm. All eyes were examined 1 month postoperatively. Flap thickness was assessed with anterior segment optical coherence tomography using the manual flap tool at 5 locations on a horizontal B scan. This study comprised 50 eyes of 25 patients (mean age 28 years ±5.72 [SD]); 42 eyes completed 6 months of follow-up. Preoperatively, the mean sphere was -3.61 ± 1.87 diopters (D) and the mean cylinder, -1.08 ± 1.23 D. Six months postoperatively, no eye lost lines of corrected distance visual acuity (CDVA), 29% gained 1 line, and 7% gained 2 lines. The mean spherical equivalent was -0.03 ± 0.42 D (range -0.88 to +0.88 D); 86% had an uncorrected distance visual acuity of 20/20 or better. The mean central flap thickness at 1 month was 102.98 ± 6.33 μm (range 91 to 114 μm). There were no intraoperative or postoperative complications. No significant complications occurred after treatment with this new femtosecond-laser platform in thin-flap LASIK. Clinical (visual and refractive) results were satisfactory in terms of safety, predictability, and stability. Dr. Henderson is a consultant to Alcon Laboratories, Inc., and Baush & Lomb, Inc. No other author has a financial or proprietary interest in any material or method mentioned.
    No preview · Article · Jun 2013 · Journal of Cataract and Refractive Surgery

  • No preview · Article · Oct 2012 · Ophthalmology
  • Bonnie An Henderson · Julia Schneider
    [Show abstract] [Hide abstract]
    ABSTRACT: Benefits of sequential surgery include assessment of the outcome of the first surgery to tailor the surgical technique, intraocular lens (IOL) power, and choice of IOL for the second surgery. Additionally, recovery may be prolonged from corneal edema, anterior chamber inflammation, or cystoid macular edema. Allowing the patient to maintain visual function in one eye during the recovery of the other eye can be important. Therefore, the few benefits of simultaneous surgery are greatly outweighed by risks of bilateral complications, inability to foresee refractive outcome, inability to alter IOL choice, potential loss of physician reimbursement, and possible increased legal ramifications.
    No preview · Article · Sep 2012 · Survey of Ophthalmology
  • Bonnie A Henderson · E Bo Yang
    [Show abstract] [Hide abstract]
    ABSTRACT: To present a simple technique to remove a one-piece, acrylic AcrySof (Alcon Laboratories Inc) intraocular lens (IOL) via the original incision. The AcrySof IOL is removed via the original (2.75-mm) incision, without cutting or folding the IOL or widening the incision. After the IOL is viscodissected from the capsular bag and brought into the anterior chamber, toothed forceps hold the optic through the incision while the manipulator enters the side-port incision and hooks onto the optic 180° away. With the forceps pulling and the lens manipulator pushing the IOL toward the incision, the IOL will fold and be delivered. A one-piece, acrylic (Acrysof) IOL can be removed without cutting or folding the lens and without widening the original 2.75-mm incision.
    No preview · Article · Jun 2012 · Journal of refractive surgery (Thorofare, N.J.: 1995)
  • J Y Kim · M-W Jo · S C Brauner · Z Ferrufino-Ponce · R Ali · S L Cremers · B A Henderson

    No preview · Article · Apr 2012 · Eye (London, England)
  • Julia Schneider · Bonnie An Henderson

    No preview · Article · Jan 2012 · International ophthalmology clinics
  • J Y Kim · M-W Jo · S C Brauner · Z Ferrufino-Ponce · R Ali · S L Cremers · B A Henderson

    No preview · Article · Nov 2011 · Eye (London, England)
  • Bonnie An Henderson · Richard Potvin

    No preview · Article · Sep 2011 · Ophthalmology
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution (bromfenac) 0.09% dosed once daily for the treatment of ocular inflammation and pain after cataract surgery with posterior chamber intraocular lens implantation. Randomized, double-masked, vehicle-controlled or active-controlled, multicenter, clinical trials. A total of 872 subjects (872 study eyes: bromfenac in 584, placebo in 288). Four randomized, double-masked, vehicle or active-controlled, clinical trials were conducted at 134 ophthalmology clinics in the United States. Subjects aged ≥ 18 years were randomized to receive either bromfenac 0.09% or placebo dosed once daily beginning 1 day before cataract surgery (day -1), continuing on the day of surgery (day 0), and continuing for an additional postoperative 14 days. Subjects were evaluated for efficacy and safety on days 1, 3, 8, 15, and 22. The primary efficacy end point was cleared ocular inflammation, measured by the summed ocular inflammation score (SOIS; anterior chamber cells and flare) by day 15. The secondary efficacy end point was the number of subjects who were pain-free at day 1. The data from the 4 trials were pooled for analyses. The SOIS and ocular pain. The proportion of subjects who had cleared ocular inflammation by day 15 was significantly higher in the bromfenac 0.09% group than in the placebo group (P < 0.0001). The mean SOIS in the bromfenac 0.09% group was significantly lower than in the placebo group at days 3, 8, 15, and 22 (P < 0.0001). The proportion of subjects who were pain-free at days 1, 3, 8, and 15 was significantly higher in the bromfenac 0.09% group than in the placebo group (P < 0.0001). The incidence of adverse events reported in the bromfenac 0.09% group was significantly lower than in the placebo group (P < 0.0001). On day 15, 84.0% of the bromfenac subjects had ≥ 1-line improvement in visual acuity compared with 66.1% of placebo subjects (P < 0.0001). Bromfenac 0.09% dosed once daily was clinically safe and effective for reducing and treating ocular inflammation and pain associated with cataract surgery. Proprietary or commercial disclosure may be found after the references.
    No preview · Article · Jul 2011 · Ophthalmology

Publication Stats

371 Citations
131.72 Total Impact Points


  • 2014-2015
    • Tufts University
      • Department of Ophthalmology
      Бостон, Georgia, United States
    • University of Toronto
      Toronto, Ontario, Canada
  • 2006-2014
    • University of Massachusetts Boston
      Boston, Massachusetts, United States
  • 2013
    • University of Crete
      • Institute of Vision and Optics (IVO)
      Retimo, Crete, Greece
  • 2005-2012
    • Harvard University
      Cambridge, Massachusetts, United States
  • 2005-2011
    • Harvard Medical School
      Boston, Massachusetts, United States